AddLife AB (ALIF-B) Fair Value & Analysis
Healthcare · SE · Market cap 20.2B SEK
Fair value as of: Aug 13, 2026
From 24 valuation models · updated today
Share price −3.7% over the past month.
A solid business, but screening 49% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (kr 107.54). The favourable scenario is already priced in.
- Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range kr 54.95 – kr 379.11 · fair‑value band kr 60.87 – kr 107.54 · the kr 157.60 price screens above the kr 81.17 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
AddLife AB (ALIF-B) currently trades at kr 157.60, while our model-based Fair Value estimate is kr 81.17, implying the stock looks roughly 48.5% overvalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, AddLife AB generated revenue of 10.4B SEK at a net margin of 5.5%. Revenue declined 2.1% year over year. It earns a return on equity of 10.6%. Net debt stands at 4.0B SEK. Fundamentals as of Aug 13, 2026
Our scenario range runs from kr 60.87 (bear case) to kr 107.54 (bull case); at kr 157.60, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 24% below its 52-week high and 22% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -46% fair-value upside, at -49%, ALIF-B screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (kr 163.26) versus Asset-Based (kr 31.09). Highest evidence: Growth DCF (80).
Notify me when ALIF-B reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 64 · Market factors (momentum, volatility) 41
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
AddLife AB (publ), together with its subsidiaries, provides instruments and equipment, consumables, and reagents primarily to medical care, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech.
Full company description
AddLife AB (publ), together with its subsidiaries, provides instruments and equipment, consumables, and reagents primarily to medical care, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory analysis. It offers products and solutions, including analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical services; and in the areas of microbiology, clinical chemistry, coagulation, molecular biology, research, immunology, point-of-care testing, veterinary diagnostics, as well as in the food industry. This segment also provides training programs for its customers. The Medtech segment provides medical device products for surgery, orthopaedics, critical care, endoscopy, wound care, healthcare IT, ophthalmology, home adaptation, and technical aids, as well as surgical procedures, welfare technology, and assistive devices for the elderly and disabled. It operates in Sweden, the United Kingdom, Ireland, Spain, Denmark, Norway, Italy, Finland, Switzerland, Germany, Poland, Austria, rest of Europe, and internationally. AddLife AB (publ) was founded in 1906 and is based in Stockholm, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
AddLife AB reported revenue of kr 10.4B in FY2025 versus kr 8.0B in FY2021, a compound +6.9%/yr. Reported net income was kr 560M in FY2025, compounding −6.1%/yr from FY2021.
of which total revenue +21.6 pp · buybacks/dilution −4.1 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
ALIF-B screens 49% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 201 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $401.27 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €164.40 | €68.55 | -58% |
| Medline Inc MDLN | $35.50 | $30.15 | -15% |
| Becton, Dickinson and Company BDX | $181.41 | $100.46 | -45% |
| Alcon Inc ALC | $73.58 | $39.78 | -46% |
| ResMed Inc RMD | $226.00 | $187.89 | -17% |
| West Pharmaceutical Services, Inc WST | $352.29 | $141.58 | -60% |
| Sartorius Stedim Biotech S.A DIM | €180.30 | €48.88 | -73% |
| Straumann Holding STMN | CHF 102.05 | CHF 47.31 | -54% |
| Coloplast A/S COLOB | kr 429.70 | kr 382.22 | -11% |
Compare AddLife AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is AddLife AB (ALIF-B) overvalued or undervalued?
What is the fair value of ALIF-B?
What is the quality score of ALIF-B?
What is the revenue of AddLife AB (ALIF-B)?
What is the net profit margin of ALIF-B?
Does AddLife AB pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track AddLife AB and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.